Balyasny Asset Management LLC Iovance Biotherapeutics, Inc. Call Options Transaction History

Balyasny Asset Management LLC

13 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	BUY	$7.28 - $11.9 $2.91 Million - $4.76 Million	400,000 New	400,000 $3.76 Million
Q3 2023 Nov 14, 2023	BUY	$4.44 - $8.79 $6.35 Million - $12.6 Million	1,430,000 New	1,430,000 $6.51 Million
Q4 2022 Feb 14, 2023	SELL	$5.62 - $10.0 $2.33 Million - $4.15 Million	-415,000 Reduced 76.15%	130,000 $830,000
Q3 2022 Nov 14, 2022	BUY	$9.53 - $13.11 $2.62 Million - $3.61 Million	275,400 Added 102.15%	545,000 $5.22 Million
Q2 2022 Aug 15, 2022	SELL	$6.38 - $18.33 $3.64 Million - $10.5 Million	-570,400 Reduced 67.9%	269,600 $2.98 Million
Q1 2022 May 16, 2022	BUY	$12.38 - $19.1 $2.6 Million - $4.01 Million	210,000 Added 33.33%	840,000 $14 Million
Q4 2021 Feb 14, 2022	BUY	$16.55 - $27.63 $413,750 - $690,750	25,000 Added 4.13%	630,000 $12 Million
Q3 2021 Nov 15, 2021	BUY	$20.35 - $26.63 $11 Million - $14.4 Million	540,000 Added 830.77%	605,000 $14.9 Million
Q2 2021 Aug 16, 2021	SELL	$16.33 - $33.07 $16,329 - $33,070	-1,000 Reduced 1.52%	65,000 $1.69 Million
Q4 2020 Feb 16, 2021	SELL	$28.04 - $50.26 $21.3 Million - $38.1 Million	-759,000 Reduced 92.0%	66,000 $3.06 Million
Q3 2020 Nov 16, 2020	BUY	$27.75 - $36.3 $22.5 Million - $29.4 Million	810,000 Added 5400.0%	825,000 $27.2 Million
Q2 2020 Aug 14, 2020	SELL	$27.21 - $41.0 $5.18 Million - $7.8 Million	-190,200 Reduced 92.69%	15,000 $412,000
Q1 2020 May 15, 2020	BUY	$19.54 - $38.85 $4.01 Million - $7.97 Million	205,200 New	205,200 $6.14 Million

312

237M

3.77M

1.7M

Ticker IOVA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 157,800,992
Market Cap $1.01B
Description
Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment o...

Get notified when there are updates to the investment portfolio of Balyasny Asset Management LLC, based on Form 13F filings with the SEC.

Stay updated on Balyasny Asset Management LLC with notifications on news.